AB-1009 Gene Therapy Enters Clinical Trials for Late-Onset Pompe Disease The FDA has cleared AB-1009, an AAV-based gene therapy for late-onset Pompe disease, for phase 1/2 clinical trials.

AB-1009, an adeno-associated virus-based investigational gene therapy for late-onset #PompeDisease, has advanced to phase 1/2 clinical testing in the United States, AskBio announced.

Read more: https://bit.ly/4r3ArhA

#RareDisease #GeneTherapy #AB1009 #ClinicalTrial #LOPD